Wave Life Sciences to Announce Interim Data for WVE-007 Phase 1 Trial on December 8, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 11 hour ago0mins
- Clinical Trial Progress: Wave Life Sciences will announce interim data for WVE-007 on December 8, 2025, targeting obesity with its proprietary SpiNA design, which could potentially transform obesity treatment paradigms.
- Innovative Drug Mechanism: WVE-007 targets INHBE mRNA to improve weight and metabolic health, with preclinical studies indicating that it can double weight loss in mice when combined with semaglutide, highlighting its significance in obesity therapy.
- Trial Design: The INLIGHT clinical trial is the first human trial for WVE-007, utilizing a 3:1 active to placebo ratio to assess safety, tolerability, and metabolic health biomarkers, demonstrating the company's strategic positioning in the obesity sector.
- Company Vision: Wave Life Sciences aims to achieve scientific breakthroughs through its RNA medicines platform PRISM®, advancing treatments for both rare and common diseases, showcasing its leadership and innovation in the biotechnology field.
WVE.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on WVE
Wall Street analysts forecast WVE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WVE is 18.09 USD with a low forecast of 9.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.620
Low
9.00
Averages
18.09
High
26.00
Current: 7.620
Low
9.00
Averages
18.09
High
26.00
Truist
Buy
maintain
$36
2025-10-29
Reason
Truist
Price Target
$36
2025-10-29
maintain
Buy
Reason
Truist reiterated a Buy rating and $36 price target on Wave Life Sciences after the company presented new data from its WVE-007 weight loss treatment study. WVE-007 could usher in a "new wave" of obesity therapeutics, with data showing a knockdown of Activin E in a dose-dependent manner that is squarely in "target range," the analyst tells investors in a research note. The firm noted, however, that the key unknown is how long of a follow-up may be needed in humans to see similar weight loss, and that it is widely understood that the data may need to mature to approach sema-like weight loss.
Clear Street
Bill Maughan
initiated
$22
2025-10-14
Reason
Clear Street
Bill Maughan
Price Target
$22
2025-10-14
initiated
Reason
Clear Street analyst Bill Maughan initiated coverage of Wave Life Sciences with a Buy rating and $22 price target. The company has proven it can produce "first-in-class and best-in-class" genetic medicines, the analyst tells investors in a research note. The firm says Wave Life has a deep pipeline of attractive drug candidates, lead by WVE-007, which targets obesity.
Wells Fargo
Tiago Fauth
Overweight
maintain
$21 -> $18
2025-09-04
Reason
Wells Fargo
Tiago Fauth
Price Target
$21 -> $18
2025-09-04
maintain
Overweight
Reason
Wells Fargo analyst Tiago Fauth lowered the firm's price target on Wave Life Sciences to $18 from $21 and keeps an Overweight rating on the shares after the company reported AATD data update for 200 and 400 cohort. While the data support '006's MoA, they do not clearly answer whether '006 can increase M-AAT levels to the 11microM+ threshold most investors were hoping for and potential positioning vs competitive landscape/modalities.
B. Riley
B. Riley
Buy
maintain
$19
2025-09-04
Reason
B. Riley
B. Riley
Price Target
$19
2025-09-04
maintain
Buy
Reason
B. Riley reiterates a Buy rating on Wave Life Sciences with a $19 price target after the company announced RestorAATion-2 data. The data were positive and demonstrated first-ever therapeutic restoration of acute phase response in homozygous for the Z mutation alpha-1antitrypsin deficiency patients, the analyst tells investors in a research note. Riley believes the disclosure de-risks both WVE-006 and Wave Life's next RNA-editing candidate. It thinks RNA editing may be a safer alternative to gene editing, and sees a "material disconnect" between Wave Life's current valuation and its multi-asset probability-weighted commercial opportunity. The firm remains an "aggressive" buyer of the stock.
See All Ratings
About WVE
Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?